Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis
Authors' conclusion
Switching to oral semaglutide ameliorated β-cell function compared with DPP-4is, presumably via tissue-to-tissue crosstalk between liver and β-cells.
Study context
- Population
- Subjects with T2D treated with DPP-4isanalysed
- Participants
- 146 subjects
- Comparison
- Switch to oral semaglutide vs DPP-4i continuation
- Semaglutiden = 69
- DPP-4in = 77reference
- Primary endpoint
- Changes in β-cell function markers, incl. Homeostatic model assessment (HOMA2) scores and disposition index (DI)
- Follow-up
- 24 weeks
Methodological detailsmulticenter, prospective
- Multicenter
- Prospective
Primary result
As reported in the abstract
- Semaglutide vs DPP-4i: P = 0.001
- Semaglutide vs DPP-4i: P < 0.001
Further findings
Glycemic control, liver enzymes, lipids (semaglutide) · 24 weeks
- Glycemic control, liver enzyme deviations and lipid profiles improved in the semaglutide group
Correlates of disposition index (DI) improvement (semaglutide)
- DI improvement correlated significantly with changes in body mass index (BMI), HbA1c and fatty liver index
- Semaglutide dose ≥ 7 mg/day, reduction in fatty liver index and metformin nonuse independently associated with DI improvement (multiple linear regression)
Original publication
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis. J Clin Endocrinol Metab. Published 2 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →